Skip to main content
Swedish Orphan Biovitrum logo

Swedish Orphan Biovitrum — Investor Relations & Filings

Ticker · SOBI ISIN · SE0000872095 LEI · 549300124Y3MQI87PT35 ST Manufacturing
Open in API
Filings indexed 892 across all filing types
Latest filing 2014-10-30 Report Publication Anno…
Country SE Sweden
Listing ST SOBI

About Swedish Orphan Biovitrum

https://www.sobi.com/en

Swedish Orphan Biovitrum (Sobi) is a specialized biopharmaceutical company dedicated to developing and delivering innovative treatments for rare and debilitating diseases. The company's primary focus is on the therapeutic areas of haematology and immunology, with a significant legacy and continued leadership in haemophilia care. Sobi addresses the high unmet medical needs of patients by advancing a pipeline of innovative medicines and working to expand patient access globally. The company's mission is to transform the lives of people affected by rare conditions through dedicated research, development, and global collaboration.

Recent filings

Filing Released Lang Actions
Report Publication Announcement 2014
Report Publication Announcement Classification · 99% confidence The document is titled with a period indicator ("*Q3 2014*") and contains a detailed 'Innehållsförteckning' (Table of Contents) listing sections like 'Bokslutskommuniké' (Financial Statement Release), 'Ekonomisk översikt' (Financial Overview), and 'Finansiell information' (Financial Information). The text includes detailed financial tables comparing Q3 2014 results against Q3 2013, covering revenue, gross margin, EBITA, and net income for the period. The content is comprehensive, covering operational highlights, management commentary ('VD har ordet'), and detailed financial breakdowns for a specific interim period (Q3). This structure strongly indicates a comprehensive quarterly financial report, which corresponds to the Interim / Quarterly Report category (IR). It is not an Earnings Release (ER) because it is too detailed and comprehensive, nor is it an Annual Report (10-K) as it covers only Q3.
2014-10-30 Swedish
Interim / Quarterly Report 2014
Interim / Quarterly Report Classification · 100% confidence The document is a comprehensive quarterly financial report for Sobi (Swedish Orphan Biovitrum AB) for Q3 2014. It contains detailed financial statements, including income statements, balance sheets, cash flow analysis, and management commentary on business performance, therapeutic areas, and financial outlook. It is not a short announcement or a press release, but a full interim report, fitting the definition of an Interim / Quarterly Report (IR). Q3 2014
2014-10-30 English
Sobi publicerar resultaten för det tredje kvartalet 2014
Interim / Quarterly Report Classification · 100% confidence The document is a comprehensive quarterly financial report for Sobi (Swedish Orphan Biovitrum) for Q3 2014. It contains detailed financial statements, including income statements, cash flow analysis, segment reporting, and management commentary on business performance. It is not an announcement of a report (RPA) because it contains the actual financial data and analysis. It is not a full Annual Report (10-K) as it specifically covers the third quarter. Therefore, it is classified as an Interim/Quarterly Report. Q3 2014
2014-10-30 Swedish
Sobi publishes Report for the Third Quarter 2014
Interim / Quarterly Report Classification · 100% confidence The document is a comprehensive quarterly financial report for Sobi (Swedish Orphan Biovitrum AB) for Q3 2014. It contains detailed financial statements, including income statements, balance sheets, cash flow analysis, and management commentary on business performance, therapeutic areas, and financial outlook. It is not a short announcement or a press release, but a full interim report, fitting the definition of an Interim / Quarterly Report (IR). Q3 2014
2014-10-30 English
Sobis samarbetspartner Biogen Idec ansöker om marknadsgodkännande för Elocta(TM) (rFVIIIFc) i Europa
Regulatory Filings Classification · 90% confidence The document is a press release ("PRESSMEDDELANDE") dated October 9, 2014, announcing that Sobi's partner, Biogen Idec, has submitted a Marketing Authorisation Application (MAA) to the European Medicines Agency (EMA) for Elocta. This announcement triggers Sobi's option rights regarding commercialization. This is a specific corporate update regarding regulatory progress and partnership milestones, not a full financial report (10-K, IR), an earnings release (ER), or a general regulatory filing (RNS). It is a specific announcement related to product development and regulatory status, which fits best under a general corporate/regulatory announcement category. Since there isn't a specific code for 'Regulatory Submission Announcement' or 'Product Pipeline Update', and it is a formal announcement of a significant corporate event, it falls under the general 'Regulatory Filings' (RNS) category as a catch-all for significant, non-financial, non-management-change announcements, or potentially 'Capital/Financing Update' (CAP) if the option exercise is considered a financing event, but the primary focus is the regulatory submission. Given the nature of the announcement (a partner filing for marketing authorization), RNS is the most appropriate general regulatory category available, as it is a formal public disclosure of a material event.
2014-10-09 Swedish
Sobi's collaboration partner Biogen Idec files marketing authorisation application for Elocta(TM) (rFVIIIFc) in Europe
Regulatory Filings Classification · 92% confidence The document announces that Biogen Idec, a collaboration partner of Sobi, has submitted a Marketing Authorisation Application (MAA) for Elocta to the European Medicines Agency (EMA). This is a specific corporate event related to regulatory submission for a drug product. It is not a full annual report (10-K), an earnings release (ER), or a general investor presentation (IP). Since it details a specific regulatory action (MAA filing) that triggers an option right for Sobi, it falls under the category of a significant corporate event announcement. Given the options, this type of specific regulatory/legal/transactional update that doesn't fit neatly into the primary financial reports (10-K, IR, ER) is best classified as a general Regulatory Filing (RNS) or potentially a Legal Proceedings Report (LTR) if it were a lawsuit, but MAA filing is a standard regulatory step. Since there is no specific code for 'Regulatory Submission Announcement', RNS serves as the most appropriate general regulatory announcement fallback, although it is highly specific. Given the context of drug development milestones, it is a significant corporate event announcement. It is not a transaction (TAR), nor a director dealing (DIRS). It is a specific regulatory step announcement, making RNS the best fit among the provided codes for non-standard, material announcements.
2014-10-09 English

Browse filings by year

20 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.